HSV-1 oncolytic virus therapeutic - BullFrog AI
Alternative Names: Modified HSV-1 therapeutic - BullFrog AILatest Information Update: 03 Apr 2024
At a glance
- Originator BullFrog AI; J. Craig Venter Institute
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Colorectal cancer
Most Recent Events
- 29 Mar 2024 HSV-1 oncolytic virus therapeutic - BullFrog AI is available for licensing as of 29 Mar 2024. https://bullfrogai.com/pipeline/